Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.
Where this comes from
- Record sourced from PubMed, PMID 31732674.
- Also identified by DOI 10.2967/jnumed.119.228858 and PMC identifier 8801958.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and predictive biomarkers in breast cancer. PET using ER- and PR-specific radioligands enables a whole-body, noninvasive assessment of receptor expression. Recent investigations of ER imaging with <sup>18</sup>F-fluoroestradiol have focused on diagnosing ER-positive metastatic disease, optimizing ER-targeted drug dosage, and predicting endocrine therapy benefit. Studies of PR imaging with <sup>18</sup>F-fluorofuranyl norprogesterone have investigated how imaging changes in PR expression as a downstream target of ER activation may reflect an early response to ER-targeted therapy. This focused review highlights recent achievements in preclinical and clinical imaging of ER and PR in breast cancer.
Medical subject headings
- Breast Neoplasms
- Diagnostic Imaging
- Receptors, Estrogen
- Receptors, Progesterone